Johnson & Johnson and Protagonist won FDA approval for Icotyde (icotrokinra), an oral IL‑23 receptor antagonist for moderate‑to‑severe plaque psoriasis in adults and adolescents 12 and older. The clearance follows four pivotal phase III studies that met primary endpoints and demonstrated a favorable safety profile across ~2,500 patients. J&J projects Icotyde could reshape psoriasis care by offering a pill alternative to established injectable IL‑23 biologics. Analysts cited peak sales potential exceeding $5 billion, driven by convenience and broader patient uptake. The approval marks the first oral peptide IL‑23 agent cleared in the U.S., narrowing the efficacy gap with injectable standards of care. Regulatory dossiers and post‑launch pricing/reimbursement decisions will determine real‑world uptake. Clinicians will seek head‑to‑head evidence and longer‑term safety data as patients and payers evaluate switching from injectables.